Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
NCT ID: NCT04412863
Last Updated: 2024-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
84 participants
INTERVENTIONAL
2020-07-03
2024-03-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B
NCT06092333
Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
NCT04856085
Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients
NCT00402428
Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3
NCT00411385
A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B
NCT02598063
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1d
VIR-2218 given by subcutaneous injection
VIR-2218
VIR-2218 given by subcutaneous injection
Cohort 2d
VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
VIR-2218
VIR-2218 given by subcutaneous injection
pegylated interferon-alfa 2a
pegylated interferon-alfa 2a given by subcutaneous injection
Cohort 3d
VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
VIR-2218
VIR-2218 given by subcutaneous injection
pegylated interferon-alfa 2a
pegylated interferon-alfa 2a given by subcutaneous injection
Cohort 1e
VIR-2218 given by subcutaneous injection
VIR-2218
VIR-2218 given by subcutaneous injection
Cohort 2e
VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
VIR-2218
VIR-2218 given by subcutaneous injection
pegylated interferon-alfa 2a
pegylated interferon-alfa 2a given by subcutaneous injection
Cohort 3e
VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
VIR-2218
VIR-2218 given by subcutaneous injection
pegylated interferon-alfa 2a
pegylated interferon-alfa 2a given by subcutaneous injection
Cohort 1f
VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
VIR-2218
VIR-2218 given by subcutaneous injection
pegylated interferon-alfa 2a
pegylated interferon-alfa 2a given by subcutaneous injection
Cohort 2f
VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
VIR-2218
VIR-2218 given by subcutaneous injection
pegylated interferon-alfa 2a
pegylated interferon-alfa 2a given by subcutaneous injection
Cohort 3f
VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
VIR-2218
VIR-2218 given by subcutaneous injection
pegylated interferon-alfa 2a
pegylated interferon-alfa 2a given by subcutaneous injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VIR-2218
VIR-2218 given by subcutaneous injection
pegylated interferon-alfa 2a
pegylated interferon-alfa 2a given by subcutaneous injection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Chronic HBV infection for \>/= 6 months
Exclusion Criteria
* Significant fibrosis or cirrhosis
* History or evidence of drug or alcohol abuse
* History of intolerance to SC injection
* History of chronic liver disease from any cause other than chronic HBV infection
* History of hepatic decompensation
* Any prior receipt of an interferon product
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alnylam Pharmaceuticals
INDUSTRY
Vir Biotechnology, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Investigative Site
Birtinya, Queensland, Australia
Investigative Site
Fitzroy, Victoria, Australia
Investigative site
Hong Kong, , Hong Kong
Investigative Site
Batu Caves, , Malaysia
Investigative Site
Kajang, , Malaysia
Investigative Site
Kuala Lumpur, , Malaysia
Investigative Site
Kuantan, , Malaysia
Investigative Site
Auckland, , New Zealand
Investigative Site
Auckland, , New Zealand
Investigative Site
Busan, , South Korea
Investigative Site
Chuncheon, , South Korea
Investigative Site
Daegu, , South Korea
Investigative Site
Seoul, , South Korea
Investigative Site
Seoul, , South Korea
Investigative Site
Yangsan, , South Korea
Investigative Site
Bangkok, , Thailand
Investigative Site
Bangkok, , Thailand
Investigative Site
Bangkok, , Thailand
Investigative Site
Chiang Mai, , Thailand
Investigative Site
Hat Yai, , Thailand
Investigative Site
Khlong Luang, , Thailand
Investigative Site
Khon Kaen, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VIR-2218-1001-PEG-IFNα
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.